Espen 60 NingF.TuomilehtoJ.PyoralaK.OnatA.SoderbergS.QiaoQ.et al (2010)

Several active research areas include: Metabolic dysfunction-associated steatotic liver disease (MASLD) : Multiple trials are evaluating semaglutide's effects on liver fat content and biomarkers, with preliminary data suggesting potential benefits in reducing hepatic steatosis and improving liver enzyme profiles Chronic kidney disease : Studies examining renal outcomes in patients with type 2 diabetes and established kidney disease, building on secondary analyses from SUSTAIN 6 showing reduced progression of diabetic nephropathy Obstructive sleep apnea : Ongoing trials investigating whether weight loss achieved with semaglutide improves sleep apnea severity and related cardiovascular outcomes Addiction and substance use disorders : Early-phase research exploring GLP-1 receptor agonists' potential effects on reward pathways and addictive behaviors, though this remains highly preliminary Alzheimer's disease and cognitive function : Preclinical evidence suggesting neuroprotective properties has prompted clinical trials examining cognitive outcomes in at-risk populations Researchers are also investigating combination therapies , such as cagrilintide plus semaglutide (CagriSema), which is currently under development

Comparing GLP-1 options when coverage changes If your Anthem coverage changes, you may need to switch between medications
Most of the time, we can help you stay on treatment
The team tracks improvements in cholesterol, blood sugar, A1C, and other health markers alongside your weight loss
~ AlphaMD You notice it one morning: a subtle tenderness behind the nipple, maybe a slight puffiness that wasn't there before